September 14, 2021

Press release

FluoGuide proceeds to seventh dose level (36 mg) with FG001 in the ongoing clinical phase I/II trial following continued improvement of tumor illumination with increasing doses

Copenhagen, Denmark, 14 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 was well tolerated,... [Read more]

August 26, 2021

Press release

FluoGuide announces regulatory approval from Swedish Authorities (MPA and Ethics committee) to commence Phase II clinical trial with FG001 in guiding surgery of high grade glioma in Sweden

Copenhagen, Denmark, 26 August 2021 – FluoGuide A/S (“FluoGuide” or “the Company”) is pleased to announce that the company has received... [Read more]

August 25, 2021

Press release

FluoGuide A/S publishes interim report for the period January – June 2021

Copenhagen, Denmark, 25 August 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January... [Read more]

August 23, 2021

Press release

Publication of promising preclinical data on FG001s effect in treatment of cancer

Copenhagen, Denmark, 23 August 2021. FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce the first publication of preclinical data... [Read more]

August 20, 2021

Press release

FluoGuide receives tranche of EUR 750,000 under its ongoing grant from EIC Accelerator – SME Instrument under European Union for FG001

Copenhagen, Denmark, 20 August 2021 FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Company has received a... [Read more]

August 17, 2021

Press release

FluoGuide proceeds to sixth dose level with FG001 in the ongoing clinical phase I/II trial following strong data from the concluded evening dosing

Copenhagen, Denmark, 17 August 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to report that FG001 was well tolerated,... [Read more]

June 30, 2021

Press release

FluoGuide enters agreement with Swedish university hospital for the second phase of the ongoing FG001 clinical trial

Copenhagen, Denmark, 30 June 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Company has entered... [Read more]

June 21, 2021

Press release

Minutes from Extraordinary General Meeting in FluoGuide A/S

Copenhagen, Denmark, 21 June 2021 – FluoGuide A/S, CVR no. 39 29 64 38 (“FluoGuide” or the “Company”) held an extraordinary... [Read more]

June 17, 2021

Press release

New article reveals promising results of using FluoGuide’s FG002 technology in guiding surgical removal of cancer

Copenhagen, Denmark, 17 June 2021 FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that promising preclinical data with the... [Read more]